Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 9/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.34 |
| ▸ | TTBK1 | Q5TCY1 | 4/20 | 0.33 |
| ▸ | TTBK2 | Q6IQ55 | 4/20 | 0.33 |
| ▸ | NEK2 | P51955 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 2/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.31 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9918523 | 0.84 | MAPT (0.41) | TTBK1TTBK2EGFRAURKB | |
| SCHEMBL9918524 | 0.78 | TTBK1 (0.41) | RETLRRK2TTBK1TTBK2 | |
| SCHEMBL9918520 | 0.77 | CSF1R (0.32) | LRRK2JAK2JAK1TYK2EGFR | |
| SCHEMBL9918522 | 0.77 | CSF1R (0.38) | TTBK1TTBK2EGFR | |
| SCHEMBL12832928 | 0.72 | LRRK2 (0.45) | LRRK2JAK2JAK1TYK2 | |
| SCHEMBL9921765 | 0.72 | TTBK1 (0.40) | LRRK2TTBK1TTBK2JAK2EGFR | |
| SCHEMBL12833307 | 0.71 | LRRK2 (0.43) | RETLRRK2TTBK1TTBK2 | |
| SCHEMBL9918542 | 0.70 | TTBK1 (0.37) | LRRK2TTBK1TTBK2JAK2EGFR | |
| SCHEMBL9918545 | 0.70 | CSF1R (0.46) | LRRK2 | |
| SCHEMBL9918525 | 0.70 | KCNH2 (0.33) | JAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | RET 475/4885LRRK2 1567/4885TTBK1 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.